26Apr 2023
Potential global impact of sodium–glucose cotransporter‐2 inhibitors in heart failure

Potential global impact of sodium–glucose cotransporter‐2 inhibitors in heart failure

This study evaluated the potential implications of optimal global implementation of SGLT2 inhibitors in heart failure (HF). An analytical decision study was performed using the global prevalence of HF from the Global Burden of Disease 2017 report. Exclusion criteria were applied to ascertain an SGLT2 inhibitor-eligible population, which was mapped onto global LVEF distributions from the REPORTHF registry. The number needed to treat for 3 years for the composite of worsening HF events and cardiovascular deaths was calculated from estimated event rates in the DAPAHF, EMPERORReduced, EMPERORPreserved, and DELIVER trials and projected onto the eligible population. Optimal implementation of SGLT2 inhibitors globally is projected to prevent/postpone approximately 7–8 million worsening HF events and cardiovascular deaths over 3 years.

  • #cardiology

Like

Save

Share